Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | SCN4A | P35499 | 1/20 | 0.38 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | CBFB | Q13951 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | GAK | O14976 | 3/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL407903 | 0.93 | KDM4E (0.43) | KDM4EPKMNOS3NOS2BACE1 | |
| SCHEMBL2306818 | 0.74 | SCN10A (0.36) | KDM4EPKMGAKRIPK2COQ8A | |
| SCHEMBL29550395 | 0.74 | NOS3 (0.52) | KDM4EPKMNOS3NOS2BACE1 | |
| SCHEMBL12502189 | 0.74 | NOS3 (0.52) | KDM4EPKMNOS3NOS2BACE1 | |
| SCHEMBL1894201 | 0.73 | NOS3 (0.35) | KDM4EPKMNOS3NOS2PARP1 | |
| Methane SCHEMBL28257040 | 0.72 | NOS3 (0.50) | KDM4EPKMNOS3NOS2BACE1 | |
| SCHEMBL2305037 | 0.71 | NQO2 (0.42) | KDM4ENOS3NOS2BACE1PARP1 | |
| SCHEMBL404365 | 0.71 | F7 (0.42) | KDM4EPARP1DYRK1A | |
| SCHEMBL405781 | 0.71 | HTT (0.38) | BACE1MAOB | |
| SCHEMBL407917 | 0.70 | BACE1 (0.51) | KDM4EPKMBACE1EPHX2SCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2389066-B1 | CYCLOPENTADIONE DERIVED HERBICIDES | SYNGENTA LTD (GB) | 2017-07-05 | — | — | EP | claimed |
| EP-2387569-B1 | HERBCIDES | SYNGENTA LTD (GB) | 2016-06-15 | — | — | EP | claimed |
| US-8895474-B2 | Herbicidally active cyclopentanediones and derivatives thereof, and their use in controlling weeds | SYNGENTA LIMITED (GB) | 2014-11-25 | — | — | US | claimed |
| US-8865623-B2 | Herbicidally active cyclic diones and derivatives thereof, processes for their preparation, compositions, and method of controlling weeds | SYNGENTA LIMITED (GB) | 2014-10-21 | — | — | US | claimed |
| WO-2013050938-A1 | 3,7-DIAZABICYCLO[3.3.1]NONANE AND 9-OXA-3,7-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-04-11 | — | — | WO | claimed |
| EP-2389066-B1 | CYCLOPENTADIONE DERIVED HERBICIDES | SYNGENTA LTD (GB) | 2017-07-05 | — | — | EP | disclosed |
| EP-2387569-B1 | HERBCIDES | SYNGENTA LTD (GB) | 2016-06-15 | — | — | EP | disclosed |
| US-9102642-B2 | Herbicidally active cyclic diones and derivatives thereof, processes for their preparation, compositions, and methods of controlling weeds | SYNGENTA LIMITED (GB) | 2015-08-11 | — | — | US | disclosed |
| EP-2393796-B1 | NOVEL HERBICIDES | SYNGENTA LTD (GB) | 2015-02-25 | — | — | EP | disclosed |
| US-20140378305-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2014-12-25 | — | — | US | disclosed |
| EP-2393769-B1 | NOVEL HERBICIDES | SYNGENTA LTD (GB) | 2014-12-10 | — | — | EP | disclosed |
| US-8895474-B2 | Herbicidally active cyclopentanediones and derivatives thereof, and their use in controlling weeds | SYNGENTA LIMITED (GB) | 2014-11-25 | — | — | US | disclosed |
| US-8865623-B2 | Herbicidally active cyclic diones and derivatives thereof, processes for their preparation, compositions, and method of controlling weeds | SYNGENTA LIMITED (GB) | 2014-10-21 | — | — | US | disclosed |
| US-8680339-B2 | Herbicides | SYNGENTA LIMITED (GB) | 2014-03-25 | — | — | US | disclosed |
| WO-2013050938-A1 | 3,7-DIAZABICYCLO[3.3.1]NONANE AND 9-OXA-3,7-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-04-11 | — | — | WO | disclosed |
| US-20120028800-A1 | NOVEL HERBICIDES | SYNGENTA CROP PROTECTION LLC (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120021912-A1 | NOVEL HERBICIDES | SYNGENTA CROP PROTECTION LLC (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120021909-A1 | NOVEL HERBICIDES | SYNGENTA CROP PROTECTION LLC (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120021907-A1 | NOVEL HERBICIDES | SYNGENTA CROP PROTECTION LLC (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021912-A1 | NOVEL HERBICIDES | DDT, CYP4X1, CYP1B1 | KDM4E 1092/4885PKM 2307/4885NOS3 3455/4885 |
| US-20120021909-A1 | NOVEL HERBICIDES | DDT, CYP4X1, CYP1B1 | KDM4E 1092/4885PKM 2307/4885NOS3 3455/4885 |
| US-20140378305-A1 | NOVEL HERBICIDES | DDT, CYP4X1, CYP1B1 | KDM4E 712/4885PKM 2059/4885NOS3 3561/4885 |
| US-20120021907-A1 | NOVEL HERBICIDES | DDT, CYP4X1, CYP1B1 | KDM4E 1092/4885PKM 2307/4885NOS3 3455/4885 |
| US-20120028800-A1 | NOVEL HERBICIDES | DDT, CYP4X1, CYP1B1 | KDM4E 1092/4885PKM 2307/4885NOS3 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.